Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Receivables - Net: 2022-2024

Historic Receivables - Net for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Dec 2024 value amounting to $447,000.

  • Amylyx Pharmaceuticals' Receivables - Net fell 92.37% to $132,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $132,000, marking a year-over-year decrease of 92.37%. This contributed to the annual value of $447,000 for FY2024, which is 98.88% down from last year.
  • According to the latest figures from FY2024, Amylyx Pharmaceuticals' Receivables - Net is $447,000, which was down 98.88% from $40.0 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Receivables - Net ranged from a high of $40.0 million in FY2023 and a low of $447,000 during FY2024.
  • In the last 3 years, Amylyx Pharmaceuticals' Receivables - Net had a median value of $15.3 million in 2022 and averaged $18.6 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first skyrocketed by 161.66% in 2023, then tumbled by 98.88% in 2024.
  • Over the past 3 years, Amylyx Pharmaceuticals' Receivables - Net (Yearly) stood at $15.3 million in 2022, then soared by 161.66% to $40.0 million in 2023, then plummeted by 98.88% to $447,000 in 2024.